To the full analysis
Asymchem Laboratories (Tianjin) stock: valuation and P/E
002821.SZAsymchem Laboratories (Tianjin) trades at a P/E of 46.7 (Biotechnology median 45.8, own median of recent years 37.4).
Daily figure as of 13 Nov 2026
P/E
46.7
P/S
7.4
P/B
3.1
PEG
1.15
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
46.7
Median of prior years
37.4
Reading
pricier than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 51.8 |
| 2017 | 39 |
| 2018 | 35.8 |
| 2019 | 53.5 |
| 2020 | 96.7 |
| 2021 | 98.6 |
| 2022 | 16.4 |
| 2023 | 18.5 |
| 2024 | 28.3 |
| 2025 | 29.4 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Dec 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.